MARCIO NATTAN PORTES SOUZA

Índice h a partir de 2011
4
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 28
  • bookPart
    Cefaleia
    (2022) SOUZA, Marcio Nattan Portes; SOARES NETO, Herval Ribeiro
  • conferenceObject
    Recurrent visits to the Emergency Department (ED) due to Headache: economic burden and epidemiological profile
    (2019) SOUZA, Marcio Nattan P.; CALDERARO, Marcelo; OLIVEIRA, Ana Paula D. S.; KUBOTA, Gabriel T.; ZAMBON, Lucas S.; ANGHINAH, Renato; JORDAO, Mauricio R.
  • conferenceObject
    Profile of migraine investigation in the emergency department of a tertiary hospital in Brazil: the exceeding use of Brain CT
    (2021) SOUZA, M. N.; KUBOTA, G.; FONSECA, A. P.; CALDERARO, M.; KUSTER, G.; JORDAO, M.; CARVALHO, R.; OLIVEIRA, A. P.; PINCERATO, R.
  • article 4 Citação(ões) na Scopus
    Update on Idiopathic Intracranial Hypertension Management
    (2022) SOUZA, Marcio Nattan Portes; COSTA, Barbara de Alencar Leite; SANTOS, Felipe Reinaldo Deus Ramos; FORTINI, Ida
    Background: Idiopathic Intracranial Hypertension (IIH) is a secondary headache with a steadily growing incidence. Currently, there is little evidence to guide the treatment of IIH. Objective: To review the pathophysiology of IIH, with focus on the role of obesity as a risk factor, and the implications for new therapeutic perspectives. Methods: In this narrative review, we summarized the current knowledge on treatment options highlighting available evidence for managing intracranial hypertension, obesity, and headache. Results: Clinical Presentation: headache is the most common symptom and a significant cause of quality-of-life impairment. Visual loss is common in the diagnosis. Pathophysiology: There is no unified theory able to explain all symptoms and the evolution of the disease.There is growing data pointing to metabolic changes and obesity with a central role in IIH pathophysiology. Treatment: Most published data on IIH treatment is related to pressure control and protection from visual loss. Acetazolamide and cerebrospinal fluid diversion are the best options available. Optic nerve sheath fenestration might be useful to temporally control the pressure over the optic nerve and thus protect from visual deterioration. Recently, venous sinus stenting has proven to be a safe option in selected cases. Finally, bariatric surgery has proven to effectively control elevated intracranial pressure. Conclusion: IIH is a potential cause of high disability. Early recognition is important, and treatment should be tailored to the needs of each case. There is a lack of research on headache management, which might persist after ICP control.
  • bookPart
    Cefaleia
    (2019) SOUZA, Marcio Nattan Portes
  • conferenceObject
    Online survey revealing patients' journey throughout the Brazilian healthcare system
    (2021) SOUZA, M. N.; KUBOTA, G.; SIMIONI, C.; CALDERARO, M.; MATTOS, B.; CHAVES, L.; COSTA, B.; SANTOS, F. R.; PASSARELLI, V.; FORTINI, I.
  • conferenceObject
    Migraine Burden and Impact: Survey Results From 6 Countries in South America, Asia, and Australia
    (2021) SOUZA, M. Nattan Portes; COHEN, J. M.; LENGIL, T.; DUSSELIER, M.; GEENS, M.
  • conferenceObject
    International availability of headache medications - an ongoing global survey of the International Headache Society
    (2023) PULEDDA, Francesca; BOER, Irene de; GARCIA-AZORIN, David; MESSINA, Roberta; AL-KARAGHOLI, Mohammad Al-Mahdi; SOUZA, Marcio Nattan Portes; DHAEM, Olivia Begasse de; GOICOCHEA, Maria-Teresa; TASSORELLI, Cristina; MAY, Arne
  • conferenceObject
    Profile of migraine investigation in the emergency department of a tertiary hospital in Brazil: the exceeding use of Brain CT
    (2021) SOUZA, M. N.; KUBOTA, G.; FONSECA, A. P.; CALDERARO, M.; KUSTER, G.; AO, M. Jord; CARVALHO, R.; OLIVEIRA, A. P.; PINCERATO, R.
  • article 2 Citação(ões) na Scopus
    Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I
    (2022) MELHADO, Eliana Meire; SANTOS, Paulo Sergio Faro; KAUP, Alexandre Ottoni; COSTA, Aline Turbino Neves Martins da; ROESLER, Celia Aparecida de Paula; PIOVESAN, Elcio Juliato; SARMENTO, Elder Machado; THEOTONIO, Giselle Oliveira Martins; CAMPOS, Henrique Carneiro de; FORTINI, Ida; SOUZA, Jano Alves de; MACIEL JUNIOR, Jayme Antunes; SEGUNDO, Joao Batista Alves; CARVALHO, Joao Jose Freitas de; SPEZIALI, Jose Geraldo; CALIA, Leandro Cortoni; BAREA, Liselotte Menke; QUEIROZ, Luiz Paulo; SOUZA, Marcio Nattan Portes; FIGUEIREDO, Marcos Ravi Cerqueira Ferreira; COSTA, Maria Eduarda Nobre de Magalhaes; PERES, Mario Fernando Prieto; JURNO, Mauro Eduardo; PEIXOTO, Patricia Machado; KOWACS, Pedro Andre; ROCHA-FILHO, Pedro Augusto Sampaio; MOREIRA FILHO, Pedro Ferreira; SILVA-NETO, Raimundo Pereira; FRAGOSO, Yara Dadalti
    The Brazilian Headache Society (Sociedade Brasileira de Cefaleia, SBCe, in Portuguese) nominated a Committee of Authors with the aim of establishing a consensus with recommendations regarding prophylactic treatment for episodic migraine based on articles published in the worldwide literature, as well as personal experience. Migraine affects 1 billion people around the world and more than 30 million Brazilians. In addition, it is an underdiagnosed and undertreated disorder. It is well known within the medical community of neurologists, and especially among headache specialists, that there is a need to disseminate knowledge about prophylactic treatment for migraine. For this purpose, together with the need for drug updates and to expand knowledge of the disease itself (frequency, intensity, duration, impact and perhaps the progression of migraine), this Consensus was developed, following a full online methodology, by 12 groups who reviewed and wrote about the pharmacological categories of the drugs used and, at the end of the process, met to read and establish conclusions for this document. The drug classes studied were: anticonvulsants, tricyclic antidepressants, monoclonal anti-calcitonin gene-related peptide (anti-CGRP) antibodies, beta-blockers, antihypertensives, calcium channel inhibitors, other antidepressants (selective serotonin reuptake inhibitors, SSRIs, and dual-action antidepressants), other drugs, and polytherapy. Hormonal treatment and anti-inflammatories and triptans in minimum prophylaxis schemes (miniprophylaxis) will be covered in a specific chapter. The drug classes studied for part I of the Consensus were: anticonvulsants, tricyclic antidepressants, monoclonal anti-CGRP antibodies, and beta-blockers.